Synthesis and antiviral activity of 1-(1,3-disubstitutedimidazolidyn-2-ylidene)-3-ethoxycarbonylmethylurea derivatives

References

• Krawczyk E, Łuczak M. Antiviral activity of natural compounds and their derivatives. Post Mikrobiol 2005;44:239–52
   Google Scholar
• Steiner I, Benninger F. Update on Herpes virus infections of the nervous system. Curr Neurol Neurosci Rep 2013;13:414–20
   PubMed Web of Science ®Google Scholar
• Hill GM, Ku ES, Dwarakanathan S. Herpes simplex keratitis. Dis Mon 2014;60:239–46
   PubMed Web of Science ®Google Scholar
• Wilson SS, Fakioglu E, Herold BC. Novel approaches in fighting herpes simplex virus infections. Expert Rev Anti Infect Ther 2009;7:559–68
   PubMed Web of Science ®Google Scholar
• Schubert A, Gentner E, Bohn K, et al. Single nucleotide polymorphisms of thymidine kinase and DNA polymerase genes in clinical herpes simplex virus type 1 isolates associated with different resistance phenotypes. Antiviral Res 2014;107:16–22
   PubMed Web of Science ®Google Scholar
• Yajima T, Knowlton KU. Viral myocarditis: from the perspective of the virus. Circulation 2009;19:2615–24
   Web of Science ®Google Scholar
• Andréoletti L, Lévêque N, Boulagnon C, et al. Viral causes of human myocarditis. Arch Cardiovasc Dis 2009;102:559–68
   PubMed Web of Science ®Google Scholar
• Yang D, Zhang HM, Ye X, et al. New trends in the development of treatments of viral myocarditis. In: Milei J, ed. Diagnosis and treatment of myocarditis. InTech 2013; DOI: 10.5772/54103. Available online: http://www.intechopen.com/books/diagnosis-and-treatment-of-myocarditis/new-trends-in-the-development-of-treatments-of-viral-myocarditis
   Google Scholar
• Hui-Soon L, Kyung-Lae P, Sang-Un C, et al. Effect of substituted on benzenesulfonyl motif of 4-phenyl-1-arylsulfonylimidazolidinones for their cytotoxity. Arch Pharm Res 2000;23:579–84
   PubMed Web of Science ®Google Scholar
• Il-Whan K, Sang-Hun J. Recognition of the importance of imidazolidinone motif for cytotoxity of 4-phenyl-1-arylsulfonylimidazolidinones using thiazolidine-1,1-dioxide analogs. Arch Pharm Res 2002;25:421–7
   PubMed Web of Science ®Google Scholar
• Jung SH, Lee HS, Kim NS, et al. Synthesis and cytotoxic activity of 1-(1-benzoylindoline-5-sulfonyl)-4-phenylimidazolidinones. Arch Pharm Res 2004;27:478–84
   PubMed Web of Science ®Google Scholar
• Son-Hyok K, Seong-Cheol B. Evaluation of anticancer activity of 4-vinyl-1-arylsulfonylimidazolidinones. Arch Pharm Res 2006;29:721–7
   PubMed Web of Science ®Google Scholar
• El-Deeb IM, Bayoumi SM, El-Sherbeny MA, Abdel-Aziz AA. Synthesis and antitumor evaluation of novel cyclic arylsulfonylureas: ADME-T and pharmacophore prediction. Eur J Med Chem 2010;45:2516–30
   PubMed Web of Science ®Google Scholar
• Iqbal Z, Akhtar T, Hendssbee AH, et al. Synthesis, characterization, and hypoglycemic activity of 3-(arylsulfonyl)spiroimidazolidine-2,4-diones. Monatsh Chem 2012;143:497–504
   Web of Science ®Google Scholar
• Hussain A, Kashif MK, Naseer MM, et al. Synthesis and in vivo hypoglycemic activity of new imidazolidine-2,4-dione derivatives. Res Chem Intermed 2014. [Epub ahead of print]. doi: 10.1007/s11164-014-1814-3
   Google Scholar
• LigPrep, Version 2.4. New York: Schrödinger, LLC; 2010
   Google Scholar
• Epik, Version 2.1. New York: Schrödinger, LLC; 2010
   Google Scholar
• Spartan 10. Available from: www.wavefun.com
   Google Scholar
• Pedretti A, Villa L, Vistoli G. VEGA – an open platform to develop chemo-bio-informatic applications, using plug-in architecture and script programming. J Comput Aided Mol Des 2004;18:167–73
   PubMed Web of Science ®Google Scholar
• Discovery Studio 3.1, Accelrys. San Diego, CA; 2009
   Google Scholar
• Rządkowska M, Szacoń E, Kaczor AA, et al. Synthesis, pharmacological activity and molecular modeling of 1-aryl-7-hydroxy-2,3-dihydroimidazo[1,2-a]pyrimidine-5(1H)-ones and their 6-substituted derivatives. Med Chem 2014;10:460–75
   PubMed Web of Science ®Google Scholar
• Rządkowska M, Szacoń E, Kaczor AA, et al. Synthesis, central nervous system activity, and structure–activity relationship of 1-aryl-6-benzyl-7-hydroxy-2,3-dihydroimidazo[1,2-a]pyrimidine-5(1H)-ones. Med Chem Res 2014;23:4221–37
   PubMed Web of Science ®Google Scholar
• Szacoń E, Rządkowska M, Kaczor AA, et al. Synthesis, central nervous system activity and structure-activity relationship of N-substituted derivatives of 1-arylimidazolidyn-2-ylideneurea and products of their cyclization. J Enzyme Inhib Med Chem 2015. [Epub ahead of print]. doi:10.3109/14756366.2014.965699
   Google Scholar
• Osiris Property Explorer. Available from: http://www.organic-chemistry.org/prog/peo/logS.html [last accessed 1 Dec 2014]
   Google Scholar
• http://www.arguslab.com/arguslab.com/ArgusLab.html [last accessed 1 Dec 2014]
   Google Scholar
• Reed LJ, Muench MA. A simple method of estimating fifty percent end points. Am J Hyg 1938;27:493–7
   Google Scholar
• Takenouchi T, Munekata E. Amyloid beta-peptide-induced inhibition of MTT reduction in PC12h and C1300 neuroblastoma cells: effect of nitroprusside. Peptides 1998;19:365–72
   PubMed Web of Science ®Google Scholar
• Tkaczyński T, Rządkowska M. Polish patent PL 169902; 1996
   Google Scholar
• Tkaczyński T, Rządkowska M. Polish patent PL 170445; 1996
   Google Scholar
• Rządkowska M, Tkaczyński T. Synthesis of new 1-aryl-2-imino-3-arylsulfonylimidazolidines and their pharmacological activity. Pharmazie 1997;50:822
   Web of Science ®Google Scholar
• Lee SK, Chang GS, Lee IH, et al. The PreADME:pc-based program for batch prediction of ADME properties. Istanbul, Turkey: EuroQSAR 2004, 9.5-10
   Google Scholar